Desmoid Tumors Clinical Trial
Official title:
Cryoablation for Advanced and Refractory Desmoid Tumors
Desmoid tumors, also called aggressive fibromatosis, are rare, locally invasive tumors with no potential for metastasis. The incidence is approximately 2 to 4 per million per year in the general population. The "watch and wait" policy is the standard of care for newly diagnosed patients in Europe. Patients who progress have first-line medical treatment, surgery is no longer the treatment because there is a high rate of recurrence (> 60%) and radiotherapy is not very suitable because the patients are often young and the tumors are large. Cryoablation seems to be an effective therapeutic option that should be evaluated.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01981551 -
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis
|
Phase 2 | |
| Withdrawn |
NCT00978146 -
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors
|
Phase 2 | |
| Completed |
NCT02476305 -
Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical Treatment
|
N/A |